Vertex Pharmaceuticals Incorporated (VRTX - Free Report) reported third-quarter 2020 adjusted earnings per share of $2.64, which beat the Zacks Consensus Estimate of $2.39. Moreover, earnings rose 115% year over year. Strong cystic fibrosis (“CF”) product revenues led to higher earnings in the reported quarter.
Vertex markets four medicines to treat CF, namely Kalydeco, Orkambi, Symdeko (called Symkevi in Europe) and Trikafta (called Kaftrio in Europe).
Revenues of $1.54 billion also surpassed the Zacks Consensus Estimate of $1.49 billion comprising almost fully of CF product revenues. The company recorded minimal collaborative revenues during the reported quarter. Total revenues rose 62% year over year, driven by the rapid uptake of Trikafta, a triple combination regimen, in the United States. Moreover, higher international revenues due to the reimbursement approvals received for Orkambi and Symkevi in some international markets in 2019 also drove revenues.
Quarter in Detail
Trikafta generated sales worth $960 million, compared with $918 million in the second quarter of 2020. The drug has seen solid uptake in the United States since its launch in October last year and has been a key growth driver for Vertex’s growth. Trikafta was approved by the brand name of Kaftrio in Europe in August, which is expected to contribute to international revenues in the fourth quarter and beyond.
Symdeko/Symkevi registered sales of $156 million in the quarter, down 61.4% year over year.
Kalydeco recorded sales of $194 million in the quarter, reflecting a 22.1% decrease year over year. Orkambi generated sales of $226 million in the reported quarter, down 23.9% year over year. Sales of Kalydeco, Symdeko/ Symkevi and Orkambi were hurt by patient switching to Trikafta.
Costs Rise
Adjusted operating income rose 112% to $854 million in the quarter driven by higher revenues.
Adjusted research and development (R&D) expenses rose 20.7% to $350 million in the quarter due to expansion of CF and non-CF pipeline.
Adjusted selling, general and administrative (SG&A) expenses increased 15.8% to $147 million in the reported quarter due to investments made to support the expansion of the CF business.
2020 Revenue Guidance Raised
Vertex raised its revenue guidance for the year primarily based on Trikafta’s continued strong performance year to date and the potential impact of the Kaftrio launch on fourth-quarter revenues.
The company now expects total revenues from CF products in the range of $6.0-$6.2 billion compared with the previous range of $5.7-$5.9 billion. The new guidance, at the midpoint, reflects approximately 52% growth over 2019.
Moreover, combined adjusted R&D and SG&A expense guidance for 2020 was maintained in the band of $1.95-$2 billion, which is higher than the 2019 level due to Trikafta launch-related costs and the expansion of the R&D pipeline. Adjusted tax rate is expected in the range of 20%-21% (previously 21%-22%).
Pipeline & Other Updates
In October 2020, Vertex stopped dosing and discontinued the phase II study on its investigational oral small molecule corrector, VX-814, for the treatment of alpha-1 antitrypsin deficiency (AATD), an inherited condition that raises risk for lung and liver disease. The decision was based on the liver enzyme elevations observed in some patients and the determination that it would be difficult to safely achieve targeted exposure levels and thereby meaningfully increase levels of alpha-1 antitrypsin, a protein mainly produced by the liver. The pipeline setback had hit the stock hard back then.
In September, Vertex announced a new strategic research collaboration and licensing agreement with Moderna (MRNA - Free Report) to develop lipid nanoparticles (LNPs) and mRNAs to treat CF using gene editing.
Our Take
Vertex beat estimates for both earnings and sales and also raised its revenue outlook for the year. However, shares of Vertex were down 1.8% in after-hours trading, despite the strong earnings results probably on broader market pressure. Vertex’s stock has declined 5.4% this year so far compared with a decrease of 6.9% for the industry.
In 2021, approval of Trikafta/Kaftrio in additional geographies, reimbursement agreements for Kaftrio in EU countries, and approval of all CF medicines for younger patient populations could bring additional revenues for Vertex. Trikafta/ Kaftrio is crucial for Vertex’s long-term growth as it has the potential to treat up to 90% of CF patients. Vertex’s non-CF pipeline is progressing rapidly with data in multiple diseases expected in 2020/2021.
Zacks Rank and Stocks to Consider
Vertex currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Vertex Pharmaceuticals Incorporated (VRTX - Free Report) reported third-quarter 2020 adjusted earnings per share of $2.64, which beat the Zacks Consensus Estimate of $2.39. Moreover, earnings rose 115% year over year. Strong cystic fibrosis (“CF”) product revenues led to higher earnings in the reported quarter.
Vertex markets four medicines to treat CF, namely Kalydeco, Orkambi, Symdeko (called Symkevi in Europe) and Trikafta (called Kaftrio in Europe).
Revenues of $1.54 billion also surpassed the Zacks Consensus Estimate of $1.49 billion comprising almost fully of CF product revenues. The company recorded minimal collaborative revenues during the reported quarter. Total revenues rose 62% year over year, driven by the rapid uptake of Trikafta, a triple combination regimen, in the United States. Moreover, higher international revenues due to the reimbursement approvals received for Orkambi and Symkevi in some international markets in 2019 also drove revenues.
Quarter in Detail
Trikafta generated sales worth $960 million, compared with $918 million in the second quarter of 2020. The drug has seen solid uptake in the United States since its launch in October last year and has been a key growth driver for Vertex’s growth. Trikafta was approved by the brand name of Kaftrio in Europe in August, which is expected to contribute to international revenues in the fourth quarter and beyond.
Symdeko/Symkevi registered sales of $156 million in the quarter, down 61.4% year over year.
Kalydeco recorded sales of $194 million in the quarter, reflecting a 22.1% decrease year over year. Orkambi generated sales of $226 million in the reported quarter, down 23.9% year over year. Sales of Kalydeco, Symdeko/ Symkevi and Orkambi were hurt by patient switching to Trikafta.
Costs Rise
Adjusted operating income rose 112% to $854 million in the quarter driven by higher revenues.
Adjusted research and development (R&D) expenses rose 20.7% to $350 million in the quarter due to expansion of CF and non-CF pipeline.
Adjusted selling, general and administrative (SG&A) expenses increased 15.8% to $147 million in the reported quarter due to investments made to support the expansion of the CF business.
2020 Revenue Guidance Raised
Vertex raised its revenue guidance for the year primarily based on Trikafta’s continued strong performance year to date and the potential impact of the Kaftrio launch on fourth-quarter revenues.
The company now expects total revenues from CF products in the range of $6.0-$6.2 billion compared with the previous range of $5.7-$5.9 billion. The new guidance, at the midpoint, reflects approximately 52% growth over 2019.
Moreover, combined adjusted R&D and SG&A expense guidance for 2020 was maintained in the band of $1.95-$2 billion, which is higher than the 2019 level due to Trikafta launch-related costs and the expansion of the R&D pipeline. Adjusted tax rate is expected in the range of 20%-21% (previously 21%-22%).
Pipeline & Other Updates
In October 2020, Vertex stopped dosing and discontinued the phase II study on its investigational oral small molecule corrector, VX-814, for the treatment of alpha-1 antitrypsin deficiency (AATD), an inherited condition that raises risk for lung and liver disease. The decision was based on the liver enzyme elevations observed in some patients and the determination that it would be difficult to safely achieve targeted exposure levels and thereby meaningfully increase levels of alpha-1 antitrypsin, a protein mainly produced by the liver. The pipeline setback had hit the stock hard back then.
In September, Vertex announced a new strategic research collaboration and licensing agreement with Moderna (MRNA - Free Report) to develop lipid nanoparticles (LNPs) and mRNAs to treat CF using gene editing.
Our Take
Vertex beat estimates for both earnings and sales and also raised its revenue outlook for the year. However, shares of Vertex were down 1.8% in after-hours trading, despite the strong earnings results probably on broader market pressure. Vertex’s stock has declined 5.4% this year so far compared with a decrease of 6.9% for the industry.
In 2021, approval of Trikafta/Kaftrio in additional geographies, reimbursement agreements for Kaftrio in EU countries, and approval of all CF medicines for younger patient populations could bring additional revenues for Vertex. Trikafta/ Kaftrio is crucial for Vertex’s long-term growth as it has the potential to treat up to 90% of CF patients. Vertex’s non-CF pipeline is progressing rapidly with data in multiple diseases expected in 2020/2021.
Zacks Rank and Stocks to Consider
Vertex currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on VRTX - FREE
Get the latest research report on MRNA - FREE
Get the latest research report on EBS - FREE